简介:PURPOSE:Toevaluatethetoxicityandresponserateofbortezomibwithconcurrentradiotherapyandtemozolomideinthetreatmentofpatientswithcentralnervoussystemmalignancies.PATIENTSANDMETHODS:Thisopen-label,dose-escalation,PhaseⅠclinicalstudyevaluatedthesafetyofthreedoselevelsofintravenouslyadministeredbortezomib(0.7,1.0,and1.3mg/m(2)/dose)onDays1,4,8,and11ofa21-daycycle,inadditiontoconcurrentradiotherapyandtemozolomideatadailydoseof75mg/m(2)startingonDay1.Theprimaryendpointwasdose-limitingtoxicity,definedasanyGrade4-5toxicityorGrade3toxicitydirectlyat-tr/butabletoprotocoltreatment,requiringhospitalizationand/orradiotherapyinterruption.
简介:PURPOSE:ThisphaseⅡtrialwasdesignedtodefinetheroleofO^6-benzylguanine(O^6-BG)inrestoringtemozolomidesensitivityinpatientswithrecurrentorprogressive,temozolomidc-resistantmalignantgliomaandtoevaluatethesafetyofadministeringO^6-BGincombinationwithtemozolomide.PATIENTSANDMETHODS:Patientswereaccruedintotwoindependentstrataonthebasisofhistology:glioblastomamultifonne(GBM)andaanaplasticglioma.BothtemozolomideandO6-BGwereadministeredonday1ofa28-daytreatmentcycle.Patientswereadministereda1-hourO^6-BGinfusionatadoseof120mg/m^2followedimmediatelybya48-hourinfusionatadoseof30mg/m^2/d.
简介:PURPOSE:Toevaluatesingle-agentactivityofbevacizumabinpatientswithrecurrentglioblastoma.PATIENTSANDMETH-ODS:Patientswithrecurrentglioblastomaweretreatedwithbevacizumab10mg/kgevery2weeks.Aftertumorprogression,patientswereimmediatelytreatedwithbevacizumabincombinationwithirinotecan340mg/m^2or125mg/m^2every2weeks,dependingonuseofenzyme-inducingantiepilepticdrugs.Completepatientevaluationswererepeatedevery4weeks.RESULTS:Forty-eightheavilypretreatedpatientswereaccruedtothisstudy.Thromboembolicevents(12.5%),hypertension(12.5%),hypophosphatemia(6%),andthrombocytopenia(6%)werethemostcommondrug-associatedadverseevents.Sixpatients(12.5%)wereremovedfromstudyfordrug-associatedtoxicity(fivethromboembolicevents,onebowelperforation).
简介:PURPOSE:Fotemustineisanitrosoureacompoundusedforthetreatmentofmalignantgliomas,especiallyinFrance.Recently,anEORTC-NCICstudyhasshownthataconcomitantcombinationofradiotherapyplustemozolomide(anoralcytotoxicdrug)improvedsurvivalinglioblastomapatients.Wesetouttotestaconcurrentcombinationofradiotherapyandfotemustinefornewlymalignantgliomas.
简介:BACKGROUND:SupratentorialPNET(sPNET)arerareCNStumorsofembryonaloriginarisinginchildrenandadults.Thetreat-mentofsPNETforallagegroupsatourcancercenterhasbeenbasedonthemanagementofmedulloblastoma(MB),involvingneurosurgicaldebulkingfollowedbyeranio-spinalirradiation(CS1)andsystemicchemotherapy.METHODS:MedicalrecordswerereviewedtogatherdemographicandclinicaldataaboutallembryonalCNStumorsinchildrenandadultsfrom2001to2007.Tumorpathology,clinicalmanagementandsurvivaldatawerealsoassessed,particularlyasregardsthosepatientswhoreceivedthePackerchemotherapyregimenforeithersPNETorMB.
简介:联接基长度对非离子与阳离子Gemini表面活性剂间相互作用的影响测定了非离子表面活性剂辛基酚醚(简称PEG—TMBPE)与三种阳离子gemini表面活性剂alkanediyl—a,x—his(dimethvldodecvIammon|umbromide)(12-s-12.S=2、4和6)复配体系的表面张力,并用小角度中子散射法测定了胶束的大小与胶团聚集数。结果表明:1)随着gemini表面活性剂连接基长度的增加以及混合体系中辛基酚醚含量的增加,两种表面活性剂之间的协同作用明显增大;2)混合胶束化是热力学自发进行的,混合胶柬的稳定顺觅序为:PEG—TMBPE+12-2—12〈PEG—TMBPE+12—4—12〈PEG—TMBPE+12—6—12。该混合体系的协同效应源于阳离子gemini表面活性剂亲水头基间的静电斥力的减小,是由以下两个因素引起的:1)辛基酚醚含量增加时使gemini表面活性剂亲水头基之间的空间位阻增大;2)12-s-12q3连接基长度增加,使阳离子gemini表面活性剂的疏水性增大,同时使其亲水头基的极性增大。